Steven A Rosenberg

List of Publications by Year in Descending Order

185 papers	30,605 citations	77 h-index	174 g-index
193 ext. papers	35,793 ext. citations	12.4 avg, IF	7.29 L-index

#	Paper	IF	Citations
185	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.. *Journal of Clinical Oncology*, **2022**, JCO2102170	2.2	6
184	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.. *Science*, **2022**, 375, eabl5447	33.3	9
183	Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. *New England Journal of Medicine*, **2022**, 386, 2112-2119	59.2	13
182	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. *Blood*, **2021**, 138, 3837-3837	2.2	1
181	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. *Journal of Clinical Investigation*, **2021**, 131,	15.9	4
180	A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types.. *Nature Cancer*, **2021**, 2, 563-574	15.4	2
179	Identification and Validation of T-cell Receptors Targeting Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. *Clinical Cancer Research*, **2021**, 27, 5084-5095	12.9	4
178	Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells. *Journal of Immunotherapy*, **2021**, 44, 1-8	5	8
177	Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing **2021**, 9,		8
176	Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma **2021**, 9,		1
175	Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. *Clinical Cancer Research*, **2021**,	12.9	9
174	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. *Science*, **2020**, 370, 1328-1334	33.3	88
173	High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12826-12835	11.5	28
172	Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells. *Journal of Immunology*, **2020**, 205, 539-549	5.3	4
171	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models **2020**, 8,		15
170	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. *Nature Communications*, **2020**, 11, 896	17.4	40
169	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. *Clinical Cancer Research*, **2020**, 26, 1267-1276	12.9	33

168	mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. *Journal of Clinical Investigation*, **2020**, 130, 5976-5988	15.9	60
167	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. *Blood*, **2020**, 136, 50-51	2.2	6
166	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. *Journal of Clinical Oncology*, **2020**, 38, 3805-3815	2.2	48
165	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee **2020**, 8,		6
164	Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. *Cancer Cell*, **2020**, 38, 454-472	24.3	53
163	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. *Cancer Immunology Research*, **2019**, 7, 1824-1836	12.5	18
162	Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. *Nature Communications*, **2019**, 10, 449	17.4	65
161	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. *Cancer Immunology Research*, **2019**, 7, 534-543	12.5	62
160	Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. *Cancer Discovery*, **2019**, 9, 1022-1035	24.4	92
159	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. *Journal of Immunology*, **2019**, 202, 3458-3467	5.3	23
158	BRAF Inhibition: Bridge or Boost to T-cell Therapy?. *Clinical Cancer Research*, **2019**, 25, 2682-2684	12.9	2
157	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. *Journal of Investigative Dermatology*, **2019**, 139, 1985-1992.e10	4.3	1
156	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. *Journal of Clinical Investigation*, **2019**, 129, 1109-1114	15.9	119
155	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. *Journal of Clinical Investigation*, **2019**, 129, 4992-5004	15.9	63
154	Tumor-infiltrating human CD4 regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. *Science Immunology*, **2019**, 4,	28	84
153	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. *Journal of Immunotherapy*, **2018**, 41, 241-247	5	25
152	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nature Medicine*, **2018**, 24, 724-730	50.5	406
151	An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. *Molecular Therapy*, **2018**, 26, 379-389	11.7	59

150	Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. *JCI Insight*, **2018**, 3,	9.9	108
149	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. *JCI Insight*, **2018**, 3,	9.9	61
148	Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. *Molecular Therapy - Methods and Clinical Development*, **2018**, 10, 371-378	6.4	15
147	T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. *Clinical Cancer Research*, **2018**, 24, 5562-5573	12.9	76
146	LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. *Cancer Research*, **2017**, 77, 1880-1891	10.1	28
145	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. *Annals of Surgical Oncology*, **2017**, 24, 947-951	3.1	19
144	Final common pathway of human cancer immunotherapy: targeting random somatic mutations. *Nature Immunology*, **2017**, 18, 255-262	19.1	260
143	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. *Science*, **2017**, 356, 200-205	33.3	231
142	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. *Lancet Oncology, The*, **2017**, 18, 792-802	21.7	136
141	A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. *Clinical Cancer Research*, **2017**, 23, 351-362	12.9	44
140	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. *Journal of Clinical Oncology*, **2017**, 35, 3322-3329	2.2	126
139	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. *Molecular Therapy*, **2017**, 25, 2245-2253	11.7	171
138	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. *Clinical Cancer Research*, **2017**, 23, 2491-2505	12.9	108
137	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. *Annals of Surgical Oncology*, **2017**, 24, 135-141	3.1	22
136	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. *Cancer Immunology Research*, **2016**, 4, 669-78	12.5	85
135	Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. *Cancer Immunology Research*, **2016**, 4, 734-43	12.5	124
134	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. *Nature Medicine*, **2016**, 22, 433-8	50.5	531
133	Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. *Molecular Therapy*, **2016**, 24, 1078-1089	11.7	43

132	Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 218-218	2.2	79
131	A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. *Human Gene Therapy Methods*, **2016**, 27, 209-218	4.9	34
130	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. *New England Journal of Medicine*, **2016**, 375, 2255-2262	59.2	681
129	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. *Journal of Clinical Oncology*, **2016**, 34, 2389-97	2.2	220
128	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. *Clinical Cancer Research*, **2016**, 22, 5480-5486	12.9	70
127	A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Clinical Cancer Research*, **2015**, 21, 1019-27	12.9	494
126	Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. *Seminars in Oncology*, **2015**, 42, 626-39	5.5	64
125	Adoptive cell transfer as personalized immunotherapy for human cancer. *Science*, **2015**, 348, 62-8	33.3	1420
124	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. *Molecular Therapy*, **2015**, 23, 1380-1390	11.7	67
123	Immunogenicity of somatic mutations in human gastrointestinal cancers. *Science*, **2015**, 350, 1387-90	33.3	465
122	Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. *Clinical Cancer Research*, **2015**, 21, 4431-9	12.9	109
121	Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. *Clinical Cancer Research*, **2015**, 21, 534-43	12.9	36
120	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. *Journal of Clinical Investigation*, **2015**, 125, 3981-91	15.9	257
119	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. *Clinical Cancer Research*, **2015**, 21, 2278-88	12.9	214
118	Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. *Journal of Virology*, **2015**, 89, 6685-94	6.6	68
117	Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy. *Blood*, **2015**, 126, 2042-2042	2.2	3
116	Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy. *Blood*, **2015**, 126, 4426-4426	2.2	9
115	Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 684-684	2.2	27

114	Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease. *Blood*, **2015**, 126, 99-99	2.2	4
113	Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. *Science*, **2014**, 344, 641-5	33.3	1097
112	Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. *Clinical Cancer Research*, **2014**, 20, 3401-10	12.9	289
111	Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. *Human Pathology*, **2014**, 45, 259-67	3.7	24
110	IL-2: the first effective immunotherapy for human cancer. *Journal of Immunology*, **2014**, 192, 5451-8	5.3	660
109	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. *Journal of Clinical Investigation*, **2014**, 124, 2246-59	15.9	664
108	Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. *Journal of Investigative Dermatology*, **2014**, 134, 2390-2398	4.3	18
107	Melanoma: Why is sentinel lymph node biopsy Standard of care for melanoma?. *Nature Reviews Clinical Oncology*, **2014**, 11, 245-6	19.4	15
106	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells **2014**, 2, 25		82
105	Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies. *OncoImmunology*, **2014**, 3, e29194	7.2	9
104	Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. *Journal of Investigative Dermatology*, **2014**, 134, 452-460	4.3	14
103	Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma. *Blood*, **2014**, 124, 550-550	2.2	23
102	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. *Journal of Clinical Oncology*, **2014**, 32, LBA3008-LBA3008	2.2	6
101	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. *Journal of Clinical Oncology*, **2014**, 32, LBA3008-LBA3008	2.2	6
100	Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. *PLoS ONE*, **2014**, 9, e93321	3.7	18
99	Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.. *Journal of Clinical Oncology*, **2014**, 32, 3079-3079	2.2	
98	Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. *Journal of Immunology*, **2013**, 190, 6034-42	5.3	118
97	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nature Medicine*, **2013**, 19, 747-52	50.5	799

96	Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. *Blood*, **2013**, 122, 1399-410	2.2	64
95	Autologous-collected anti-CD19 chimeric antigen receptor T cells (19CARTs) for pediatric acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL): Clinical activity and cytokine release without graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).. *Journal of Clinical Oncology*, **2013**, 31, 10008-10008	2.2	
94	Raising the bar: the curative potential of human cancer immunotherapy. *Science Translational Medicine*, **2012**, 4, 127ps8	17.5	189
93	Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. *Journal of Immunotherapy*, **2012**, 35, 283-92	5	87
92	Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients.. *Journal of Clinical Oncology*, **2012**, 30, 8576-8576	2.2	1
91	Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers.. *Journal of Clinical Oncology*, **2012**, 30, e14179-e14179	2.2	
90	Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. *Nature Reviews Clinical Oncology*, **2011**, 8, 577-85	19.4	256
89	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clinical Cancer Research*, **2011**, 17, 4550-7	12.9	1434
88	Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. *Molecular Therapy*, **2011**, 19, 1928-30	11.7	9
87	Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. *Clinical Cancer Research*, **2011**, 17, 5343-52	12.9	204
86	Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *Journal of Clinical Oncology*, **2011**, 29, 917-24	2.2	1185
85	T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Molecular Therapy*, **2011**, 19, 620-6	11.7	693
84	CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. *Clinical Cancer Research*, **2010**, 16, 6122-31	12.9	231
83	Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. *Molecular Therapy*, **2010**, 18, 1744-5	11.7	53
82	Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Molecular Therapy*, **2010**, 18, 843-51	11.7	1628
81	Different adjuvanticity of incomplete freund© adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. *Journal of Immunotherapy*, **2010**, 33, 626-9	5	22
80	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. *Blood*, **2010**, 116, 3875-86	2.2	239
79	Adoptive cell therapy for the treatment of patients with metastatic melanoma. *Current Opinion in Immunology*, **2009**, 21, 233-40	7.8	466

78	Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nature Reviews Cancer*, **2008**, 8, 299-308	31.3	1179
77	Overcoming obstacles to the effective immunotherapy of human cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 12643-4	11.5	39
76	Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. *Journal of Immunotherapy*, **2008**, 31, 742-51	5	193
75	Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor. *Blood*, **2008**, 112, 4623-4623	2.2	1
74	Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science*, **2006**, 314, 126-9	33.3	2001
73	IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. *Journal of Immunotherapy*, **2006**, 29, 313-9	5	341
72	Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. *Journal of Immunotherapy*, **2006**, 29, 224-31	5	28
71	Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. *Journal of Immunotherapy*, **2005**, 28, 53-62	5	167
70	Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. *Journal of Immunology*, **2005**, 175, 6169-76	5.3	391
69	T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. *Journal of Immunology*, **2004**, 172, 6057-64	5.3	89
68	Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *Journal of Immunology*, **2004**, 173, 7125-30	5.3	402
67	Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101 Suppl 2, 14639-45	11.5	289
66	Reply to "Cancer vaccines: pessimism in check". *Nature Medicine*, **2004**, 10, 1279-1280	50.5	15
65	Development of effective immunotherapy for the treatment of patients with cancer. *Journal of the American College of Surgeons*, **2004**, 198, 685-96	4.4	42
64	Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. *Human Gene Therapy*, **2003**, 14, 709-14	4.8	99
63	Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. *Journal of Immunotherapy*, **2003**, 26, 332-42	5	510
62	Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. *Journal of Immunotherapy*, **2003**, 26, 385-93	5	53
61	Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. *Clinical Cancer Research*, **2003**, 9, 2973-80	12.9	68

60	Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. *Journal of Clinical Oncology*, **2000**, 18, 1954-9	2.2	34
59	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. *International Journal of Cancer*, **2000**, 86, 818-26	7.5	50
58	Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. *Human Gene Therapy*, **2000**, 11, 2377-87	4.8	49
57	Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. *Journal of the National Cancer Institute*, **2000**, 92, 1336-44	9.7	91
56	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes **2000**, 86, 818		3
55	Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. *Journal of Experimental Medicine*, **1999**, 189, 1659-68	16.6	113
54	Human tumor antigens for cancer vaccine development. *Immunological Reviews*, **1999**, 170, 85-100	11.3	237
53	Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. *Science*, **1999**, 284, 1351-4	33.3	262
52	A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. *Nature Medicine*, **1998**, 4, 168-72	50.5	57
51	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nature Medicine*, **1998**, 4, 321-7	50.5	1539
50	Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. *Cancer*, **1998**, 83, 797-805	6.4	147
49	Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. *International Journal of Cancer*, **1998**, 75, 517-24	7.5	133
48	Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. *Annals of Surgical Oncology*, **1998**, 5, 64-76	3.1	26
47	Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer **1998**, 83, 797		1
46	Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. *Journal of the National Cancer Institute*, **1997**, 89, 1595-601	9.7	133
45	Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. *International Reviews of Immunology*, **1997**, 14, 173-92	4.6	81
44	Human tumor antigens recognized by T-cells. *Immunologic Research*, **1997**, 16, 313-39	4.3	108
43	Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. *Journal of Leukocyte Biology*, **1996**, 60, 296-309	6.5	37

42	Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. *Annals of Surgical Oncology*, **1996**, 3, 67-73	3.1	10
41	T-cell recognition of self peptides as tumor rejection antigens. *Immunologic Research*, **1996**, 15, 179-90	4.3	44
40	Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. *Nature Medicine*, **1995**, 1, 330-6	50.5	337
39	The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. *Cancer*, **1995**, 75, 1030-7	6.4	43
38	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. *Cancer*, **1995**, 76, 687-94	6.4	65
37	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma **1995**, 76, 687		1
36	Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. *Cancer*, **1994**, 73, 1731-7	6.4	186
35	Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. *Cancer*, **1994**, 74, 3212-22	6.4	90
34	Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. *International Journal of Cancer*, **1994**, 58, 69-79	7.5	69
33	Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide **1994**, 39, 105		2
32	Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response **1994**, 73, 1731		1
31	Propagation of mouse and human T cells with defined antigen specificity and function. *Novartis Foundation Symposium*, **1994**, 187, 179-93; discussion 194-7		3
30	Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. *Journal of Urology*, **1993**, 150, 463-6	2.5	104
29	Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. *Cancer*, **1992**, 69, 1850-5	6.4	53
28	Thyroid dysfunction associated with immunotherapy for patients with cancer. *Cancer*, **1991**, 68, 2384-90	6.4	61
27	Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. *Journal of Urology*, **1990**, 144, 614-7; discussion 617-8	2.5	80
26	Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. *Cancer*, **1990**, 66, 1513-6	6.4	42
25	Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. *Journal of Surgical Oncology*, **1989**, 41, 263-73	2.8	54

24	Overview of interleukin-2 as an immunotherapeutic agent. *Journal of Surgical Oncology*, **1989**, 5, 385-90		38
23	In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. *Journal of the National Cancer Institute*, **1989**, 81, 1709-17	9.7	151
22	Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. *Cancer*, **1988**, 62, 2350-3	6.4	26
21	Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma. *Clinical and Experimental Metastasis*, **1988**, 6, 387-400	4.7	2
20	High-grade soft tissue sarcomas of the extremities. *Cancer*, **1986**, 58, 190-205	6.4	247
19	A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. *Cancer Chemotherapy and Pharmacology*, **1986**, 18 Suppl 2, S25-8	3.5	52
18	A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. *Cancer*, **1985**, 55, 1206-14	6.4	124
17	Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. *Cancer*, **1985**, 55, 1327-33	6.4	104
16	Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. *Cancer*, **1985**, 55, 1361-6	6.4	128
15	A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma. *Immunopharmacology and Immunotoxicology*, **1985**, 7, 17-31		2
14	Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. *Cancer*, **1984**, 53, 896-905	6.4	99
13	The significance of bone scan abnormalities in patients with primary osteogenic sarcoma. *Journal of Surgical Oncology*, **1984**, 26, 122-9	2.8	7
12	Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. *Cancer*, **1983**, 52, 424-34	6.4	171
11	A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer*, **1981**, 47, 1746-51	6.4	60
10	The effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma. *Cancer*, **1981**, 47, 2368-74	6.4	70
9	Evaluation of computed tomography in the detection of pulmonary metastases: a prospective study. *Cancer*, **1979**, 43, 913-6	6.4	162
8	Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. *Cancer*, **1979**, 43, 2178-81	6.4	47
7	Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. *Cancer*, **1979**, 44, 2291-3	6.4	39

6	Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate. *Cancer* , **1978**, 41, 52-5	6.4	45
5	Severe thrombocytopenia following intralesional BCG therapy. *Cancer*, **1978**, 41, 820-6	6.4	14
4	Clinical and immunologic studies of disseminated BCG infection. *Cancer*, **1978**, 41, 1771-80	6.4	38
3	Clinical course and management of accidental adriamycin extravasation. *Cancer*, **1977**, 40, 2053-6	6.4	104
2	Future prospects for immunotherapy. *Cancer*, **1975**, 36, 821-4	6.4	5
1	Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade		4